Innovative Gas Sensors Expand SSB's PAT Portfolio
Sartorius Stedim Biotech (SSB), a leading international supplier of pharmaceutical and biotech equipment, has entered into a global sales partnership with BlueSens, the German experts in gasometric engineering. BlueSens is a highly specialized provider of sensor technology, which is used by the biopharmaceutical industry for inline measurement of gases in microbial fermentation and cell cultivation processes. The co-operation agreement between SSB and BlueSens provides that, alongside BlueSens, SSB will assume global marketing and distribution of its partner company’s oxygen and carbon dioxide sensors, and sell these as private label products under SSB’s brand name BioPAT Xgas.
During the past years, SSB has continuously expanded its process analytics portfolio in the area of sensor technology to measure critical process parameters, such as pH and dissolved oxygen, temperature, glucose, lactate and biomass, non-invasively and in real time. The new oxygen and carbon dioxide sensors are further important additions to SSB’s range of analytical products. BioPAT Xgas enables precise, reproducible information to be obtained about the progress of fermentation, without having to take samples and analyze them off-line in a laboratory.
Stefan Schlack, Senior Vice President of Marketing at SSB, said: "These sensors make our bioreactors even more intelligent. They analyse metabolic processes in real time during cultivation and help our customers better understand their processes. Used in combination with our software, these sensors are powerful tools for optimizing biopharmaceutical production processes and accelerating development."
Dr Holger Müller, Sales and Marketing Manager at BlueSens, stated: “In fermentation, SSB is among the leading suppliers worldwide and has a strong, global sales network. We would like to leverage these advantages to reach considerably more customers. I am looking forward to our partnership.“
BioPAT Xgas will be sold as an equipment package that includes SSB’s single-use and reusable bioreactors. Ready to use right out of the box, the sensors are completely integrated into SSB’s BioPAT DCU control units and SCADA software, called BioPAT MFCS.
In conjunction with Sartorius software, BioPAT Xgas analyses critical process variables, such as oxygen uptake rate (OUR), carbon dioxide production rate (CPR) or respiratory quotient (RQ).
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...